biostudies-literatureUnknown39(7)Zhong WZ<h4>Purpose</h4>ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.<h4>Methods</h4>From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and <i>EGFR</i>-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was Journal of clinical oncology : official journal of the American Society of Clinical Oncology713-722https://www.ebi.ac.uk/biostudies/studies/S-EPMC8078324biostudies-literatureGefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.PMC8078324Huang CWu LRen SXYu PXu STWu YLCheng YLi XFMa HTYang JJWang QLiu LXYang XNWang BHLi JLiu SYZhou QLiu YYYin RChen CYang FChen KNZhong WZYan HHMao WMXu SXu SDWei YCLiu ZDfalseGefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.<h4>Purpose</h4>ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (<i>EGFR</i>) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results.<h4>Methods</h4>From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and <i>EGFR</i>-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was 2021-01-01T00:00:00Z2021 Mar2025-04-22T01:30:44.125Z2025-04-05T19:58:20.399ZS-EPMC80783243333219010.1200/JCO.20.01820